Valuation: Samik Pharmaceutical Company LTD.

Market Cap 71.28B 53.44M 47.86M 44.03M 39.89M 74.57M 5.07B 75.96M 525M 211M 2.67B 201M 196M 8.42B P/E 2024 *
-
P/E 2025 -140x
Enterprise Value 42.23B 31.66M 28.35M 26.08M 23.63M 44.17M 3.01B 45M 311M 125M 1.58B 119M 116M 4.99B EV / Sales 2024 *
-
EV / Sales 2025 1.65x
Free-Float
40.47%
Yield 2024 *
-
Yield 2025 0.29%
1 day-8.29%
1 week-3.93%
Current month-17.39%
1 month-17.39%
3 months+66.78%
6 months-26.86%
Current year-49.32%
1 week 7,000
Extreme 7000
8,680
1 month 6,580
Extreme 6580
9,470
Current year 3,705
Extreme 3705
21,800
1 year 3,705
Extreme 3705
25,050
3 years 3,705
Extreme 3705
25,050
5 years 3,705
Extreme 3705
25,050
10 years 3,705
Extreme 3705
25,050
Manager TitleAgeSince
Chief Executive Officer 64 2016-11-30
Chief Executive Officer 59 2011-05-31
Corporate Officer/Principal 56 2018-07-31
Director TitleAgeSince
Chairman 59 2011-05-31
Chairman 64 2016-11-30
Director/Board Member 66 2024-02-29
Change 5-day change 1-year change 3-year change Capi.($)
-8.29%-3.93%-66.76% - 53.44M
+3.19%+11.31%+67.86%+150.58% 1,263B
-0.73%+3.56%+44.51%+85.81% 658B
+1.41%+3.24%+29.22%+107.83% 521B
+0.42%+3.20%+54.15%+67.18% 391B
+2.18%+2.93%+73.30%+45.62% 369B
+1.12%+4.52%+35.30%+58.08% 307B
+6.96%+8.86%+11.27%+36.62% 290B
+1.15%+6.09%+59.59%+77.06% 252B
+3.06%+9.38%+44.11%+119.47% 212B
Average +0.73%+5.20%+35.25%+83.14% 426.2B
Weighted average by Cap. +1.19%+6.60%+50.88%+98.31%

Financials

2024 2025
Net sales 55.86B 41.88M 37.51M 34.5M 31.26M 58.43M 3.98B 59.53M 411M 165M 2.09B 157M 154M 6.6B 60.02B 45M 40.3M 37.07M 33.59M 62.79M 4.27B 63.96M 442M 177M 2.25B 169M 165M 7.09B
Net income 3.52B 2.64M 2.37M 2.18M 1.97M 3.68M 251M 3.75M 25.94M 10.41M 132M 9.91M 9.7M 416M -755M -566K -507K -466K -422K -790K -53.74M -804K -5.56M -2.23M -28.27M -2.12M -2.08M -89.15M
Net Debt -12.84B -9.63M -8.62M -7.93M -7.19M -13.43M -914M -13.69M -94.59M -37.97M -481M -36.13M -35.37M -1.52B -29.05B -21.78M -19.51M -17.94M -16.26M -30.39M -2.07B -30.96M -214M -85.9M -1.09B -81.74M -80M -3.43B
Projected Income Statement - Annual - Samik Pharmaceutical Company LTD.
Logo Samik Pharmaceutical Company LTD.
Samik Pharm Co Ltd is a Korea-based company engaged in the manufacturing and sales of pharmaceuticals business. The Company is mainly engaged in the manufacture of drugs such as circulatory machinery treatments such as Cesar Plus tablets and Eravix tablets, diabetes treatments such as Griffin tablets and Gluemser tablets, digestive machinery treatments such as Samik Pharmotidine tablets and Rebacode tablets, and antipyretic anti-inflammatory drugs such as Tamitrasemi tablets and Seklfen tablets. In addition, the Company is also engaged in the manufacturing of drugs such as treating acute or recurrent vaginal candidiasis, treating children with motion sickness, and treating alopecia. The Company sells its products in domestic and overseas markets.
Employees
-
Date Price Change Volume
26-10-30 ₩7,080.00 -8.29% 958,627
26-10-29 ₩7,720.00 +0.39% 4,341,718
26-10-28 ₩7,690.00 +9.54% 4,400,245
26-10-27 ₩7,020.00 -1.96% 490,114
26-10-26 ₩7,160.00 -2.85% 306,063
  1. Stock Market
  2. Stocks
  3. A014950 Stock